Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Accumulated Expenses: 2016-2024

Historic Accumulated Expenses for Rocket Pharmaceuticals (RCKT) over the last 9 years, with Dec 2024 value amounting to $11.9 million.

  • Rocket Pharmaceuticals' Accumulated Expenses rose 10.79% to $11.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.4 million, marking a year-over-year increase of 10.79%. This contributed to the annual value of $11.9 million for FY2024, which is 20.28% up from last year.
  • Per Rocket Pharmaceuticals' latest filing, its Accumulated Expenses stood at $11.9 million for FY2024, which was up 20.28% from $9.9 million recorded in FY2023.
  • In the past 5 years, Rocket Pharmaceuticals' Accumulated Expenses ranged from a high of $11.9 million in FY2024 and a low of $4.5 million during FY2021.
  • Moreover, its 3-year median value for Accumulated Expenses was $10.0 million (2022), whereas its average is $10.6 million.
  • As far as peak fluctuations go, Rocket Pharmaceuticals' Accumulated Expenses decreased by 7.02% in 2021, and later spiked by 120.74% in 2022.
  • Over the past 5 years, Rocket Pharmaceuticals' Accumulated Expenses (Yearly) stood at $4.9 million in 2020, then decreased by 7.02% to $4.5 million in 2021, then soared by 120.74% to $10.0 million in 2022, then fell by 0.76% to $9.9 million in 2023, then rose by 20.28% to $11.9 million in 2024.